Table 1. Cost estimates used in the model.
| Service | Mean Cost (£) | |
|---|---|---|
| Pazopanib | Sunitinib | |
| Treatment initiation, per patient | 48.69 | 48.69 |
| Medication, per day | 74.72 | 112.10 |
| Dispensing, per prescription | 14.74 | 14.74 |
| Pre-progression follow-up and monitoring, per month | 153.48 | 153.48 |
| Post-progression supportive care, per month | 225.08 | 225.08 |
| Other mRCC-related care associated with pazopanib and sunitinib treatment, per month, pre-progression | ||
| Hospital days | 79.16 | 112.28 |
| Medical office visits | 12.07 | 12.76 |
| Medical/surgical specialty visits | 33.74 | 38.00 |
| Telephone consultations | 1.68 | 1.57 |
| Emergency department visits | 2.75 | 4.38 |
| Home healthcare visits | 0.77 | 3.14 |
| Laboratory visits | 1.87 | 2.41 |
| Laboratory tests | 4.78 | 4.45 |
| Radiology tests | 17.32 | 20.78 |
| Total | 154.14 | 199.77 |
| PTACT, per patient with progression | ||
| Axitinib | 895.53 | 1,296.64 |
| Bevacizumab | 1,026.32 | 829.79 |
| Everolimus | 3,374.76 | 3,259.21 |
| Pazopanib | 364.23 | 880.48 |
| Sirolimus | 3.85 | 3.85 |
| Sorafenib | 1,422.97 | 2,340.99 |
| Sunitinib | 2,690.55 | 1,487.20 |
| Temsirolimus | 592.01 | 844.75 |
| Any cytokine (assumed to be IFN-α) | 122.99 | 95.91 |
| Other (assigned same cost as IFN-α) | 226.14 | 183.82 |
| Unlicensed | 0 | 0 |
| Total | 10,899.37 | 11,222.67 |
IFN, interferon; mRCC, metastatic renal cell carcinoma; PTACT, post-treatment anti-cancer therapy.